Melek Parlak Khalily
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Melek Parlak Khalily has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Salih Özçubukçu
Department of Chemistry
6 shared publications - Sevgi Gulyuz
Marmara Research Center, The Scientific and Technological Research Council of Turkey (TUBITAK), 41470, Kocaeli, Türkiye
5 shared publications - Özgür Yılmaz
TÜBİTAK Marmara Research Center
5 shared publications - Asuman Bozkir
Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkey
4 shared publications - Umut Ugur Ozkose
Institut Charles Gerhardt, ICGM, Univ. Montpellier, CNRS, ENSCM Montpellier France
4 shared publications - Dilek Telci
Yeditepe University
3 shared publications
Latest Publications
- Open Access
- 3 May 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (3) , 430-438
Influence of TLR4 signaling on cannabidiol’s antitumor effectiveness in lung adenocarcinoma cells
Objectives: Lung cancer remains a predominant cancer type with high incidence and low survival rates. Key challenges in its treatment include impaired cellular mechanisms, notably resistance to apoptosis and altered immune responses. A critical aspect in this context is the heightened TLR4-mediated signaling, known to promote cell survival, metastasis, and resistance to cell death, particularly impacting immune microenvironment regulation. This study focuses on evaluating the impact of TLR4 signaling activation on potential therapeutic strategies. Methods: Our research utilizes cannabidiol (CBD), a compound already employed in mitigating chemotherapy side effects in lung adenocarcinoma, recognized for its antitumor properties including antiproliferative, antimetastatic, and apoptosis-inducing effects. However, the effectiveness of CBD in lung cancer cells with elevated TLR4 signaling remains uncertain. Results: Our findings reveal that the combination of CBD and TLR4 agonist affects cell viability, proliferation, cell cycle progression, apoptosis, and gene expression related to immune response and extracellular matrix regulation. In lung adenocarcinoma cells with activated TLR4, CBD shows an increased IC 50 value, reflecting reduced antiproliferative capacity. Furthermore, its efficacy in arresting the cell cycle and inducing apoptosis is also compromised. The influence on immune response and extracellular matrix regulation is also altered in TLR4-activated cells. Conclusions: These results indicate that TLR4 activation significantly diminishes the antitumor efficacy of CBD. This highlights the importance of considering TLR4 signaling activation in future research on therapeutic agents like CBD for cancer treatment.
- 3 May 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (3) , 430-438
Open AccessInfluence of TLR4 signaling on cannabidiol’s antitumor effectiveness in lung adenocarcinoma cells
Objectives: Lung cancer remains a predominant cancer type with high incidence and low survival rates. Key challenges in its treatment include impaired cellular mechanisms, notably resistance to apoptosis and altered immune responses. A critical aspect in this context is the heightened TLR4-mediated signaling, known to promote cell survival, metastasis, and resistance to cell death, particularly impacting immune microenvironment regulation. This study focuses on evaluating the impact of TLR4 signaling activation on potential therapeutic strategies. Methods: Our research utilizes cannabidiol (CBD), a compound already employed in mitigating chemotherapy side effects in lung adenocarcinoma, recognized for its antitumor properties including antiproliferative, antimetastatic, and apoptosis-inducing effects. However, the effectiveness of CBD in lung cancer cells with elevated TLR4 signaling remains uncertain. Results: Our findings reveal that the combination of CBD and TLR4 agonist affects cell viability, proliferation, cell cycle progression, apoptosis, and gene expression related to immune response and extracellular matrix regulation. In lung adenocarcinoma cells with activated TLR4, CBD shows an increased IC 50 value, reflecting reduced antiproliferative capacity. Furthermore, its efficacy in arresting the cell cycle and inducing apoptosis is also compromised. The influence on immune response and extracellular matrix regulation is also altered in TLR4-activated cells. Conclusions: These results indicate that TLR4 activation significantly diminishes the antitumor efficacy of CBD. This highlights the importance of considering TLR4 signaling activation in future research on therapeutic agents like CBD for cancer treatment.
- Open Access
- 25 April 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF CHEMISTRY
- Vol. 48 (2) , 229-236
Improving the water solubility of cannabidiol using a peptide carrier
Cannabidiol (CBD), nonpsychotropic cannabinoid found in Cannabis sativa, is a very promising drug candidate offering many differential effects such as sedative, antiinflammatory, antioxidant, and neuroprotective properties. Nevertheless, the therapeutic use of CBD is hindered by its lack of water solubility and relatively low bioavailability. Various carriers have been used to address the solubility issues of CBD and other highly lipophilic drugs so far. However, self-assembled peptide nanostructures as carrier have not been used to improve the water solubility of CBD yet. In this study, a self-assembling peptide micelle was demonstrated to be an effective vehicle for encapsulation of CBD and increased its aqueous solubility up to 2000-fold compared to CBD itself.
- 25 April 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF CHEMISTRY
- Vol. 48 (2) , 229-236
Open AccessImproving the water solubility of cannabidiol using a peptide carrier
Cannabidiol (CBD), nonpsychotropic cannabinoid found in Cannabis sativa, is a very promising drug candidate offering many differential effects such as sedative, antiinflammatory, antioxidant, and neuroprotective properties. Nevertheless, the therapeutic use of CBD is hindered by its lack of water solubility and relatively low bioavailability. Various carriers have been used to address the solubility issues of CBD and other highly lipophilic drugs so far. However, self-assembled peptide nanostructures as carrier have not been used to improve the water solubility of CBD yet. In this study, a self-assembling peptide micelle was demonstrated to be an effective vehicle for encapsulation of CBD and increased its aqueous solubility up to 2000-fold compared to CBD itself.
- Open Access
- 22 October 2023
- Published by Wiley in Macromolecular Bioscience
- Vol. 24 (3) , e2300324
A Novel PEtOx‐Based Nanogel Targeting Prostate Cancer Cells for Drug Delivery
This study focuses on creating a specialized nanogel for targeted drug delivery in cancer treatment, specifically targeting prostate cancer. This nanogel (referred to as SGK 636/Peptide 563/PEtOx nanogel) is created using hydrophilic poly(2‐ethyl‐2‐oxazoline) (PEtOx) through a combination of living/cationic ring‐opening polymerization (CROP) and alkyne‐azide cycloaddition (CuAAC) “click” chemical reactions. A fluorescent probe (BODIPY) is also conjugated with the nanogel to monitor drug delivery. The characterizations through 1H‐NMR, and FT‐IR, SEM, TEM, and DLS confirm the successful production of uniform, and spherical nanogels with controllable sizes (100 to 296 nm) and stability in physiological conditions. The biocompatibility of nanogels is evaluated using MTT cytotoxicity assays, revealing dose‐dependent cytotoxicity. Drug‐loaded nanogels exhibited significantly higher cytotoxicity against cancer cells in vitro compared to drug‐free nanogels. Targeting efficiency is examined using both peptide‐conjugated and peptide‐free nanogels, with the intracellular uptake of peptide 563‐conjugated nanogels by tumor cells being 60‐fold higher than that of nanogels without the peptide. The findings suggest that the prepared nanogel holds great potential for various drug delivery applications due to its ease of synthesis, tunable functionality, non‐toxicity, and enhanced intracellular uptake in the tumor region.
- 22 October 2023
- Published by Wiley in Macromolecular Bioscience
- Vol. 24 (3) , e2300324
Open AccessA Novel PEtOx‐Based Nanogel Targeting Prostate Cancer Cells for Drug Delivery
This study focuses on creating a specialized nanogel for targeted drug delivery in cancer treatment, specifically targeting prostate cancer. This nanogel (referred to as SGK 636/Peptide 563/PEtOx nanogel) is created using hydrophilic poly(2‐ethyl‐2‐oxazoline) (PEtOx) through a combination of living/cationic ring‐opening polymerization (CROP) and alkyne‐azide cycloaddition (CuAAC) “click” chemical reactions. A fluorescent probe (BODIPY) is also conjugated with the nanogel to monitor drug delivery. The characterizations through 1H‐NMR, and FT‐IR, SEM, TEM, and DLS confirm the successful production of uniform, and spherical nanogels with controllable sizes (100 to 296 nm) and stability in physiological conditions. The biocompatibility of nanogels is evaluated using MTT cytotoxicity assays, revealing dose‐dependent cytotoxicity. Drug‐loaded nanogels exhibited significantly higher cytotoxicity against cancer cells in vitro compared to drug‐free nanogels. Targeting efficiency is examined using both peptide‐conjugated and peptide‐free nanogels, with the intracellular uptake of peptide 563‐conjugated nanogels by tumor cells being 60‐fold higher than that of nanogels without the peptide. The findings suggest that the prepared nanogel holds great potential for various drug delivery applications due to its ease of synthesis, tunable functionality, non‐toxicity, and enhanced intracellular uptake in the tumor region.
- 6 July 2021
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 45 (32) , 14532-14547
Poly(2-ethyl-2-oxazoline-co-ethyleneimine)-block-poly(ε-caprolactone) based micelles: synthesis, characterization, peptide conjugation and cytotoxic activity
Here we present self-assembled polymeric micelles as potential delivery systems for therapeutic agents with highly tunable properties. The major goal of this study is to design breast and prostate cancer specific targeting peptide modified PEtOx-co-PEI-b-PCL block copolymer based micelles as a targetable carrier system in cancer treatment. For this, a series of micelles based on poly(2-ethyl-2-oxazoline)-co-polyethyleneimine-block-poly(ε-caprolactone) [P(EtOx-co-EI)-b-PCL] copolymers with two different proportions of PEI (30% and 60% hydrolysis degrees of PEtOx) were successfully prepared. The block copolymers were synthesized using a combination of living cationic ring-opening polymerization and a copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) click reaction. Then, peptide 18 and peptide 563 were conjugated to P(EtOx-co-EI)-b-PCL through a thiol–ene click-type reaction to obtain the desired tumor-targeting. The structural properties of the copolymers were confirmed by 1H NMR, FT-IR, UV-Vis spectrometry and GPC. Peptide and non-peptide-conjugated micelles with particle sizes between 82 ± 0.6 and 170 ± 10.7 nm were obtained by self-assembly with two different chain lengths of PEI blocks. The micelles containing the 60% PEI block showed increased zeta potential values. The cytotoxicity of the copolymers was evaluated under in vitro conditions. Overall, our results indicate that the micelles prepared with peptide-conjugated block copolymers can be used as potential nanocarriers for targeted therapeutic delivery systems.
- 6 July 2021
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 45 (32) , 14532-14547
Poly(2-ethyl-2-oxazoline-co-ethyleneimine)-block-poly(ε-caprolactone) based micelles: synthesis, characterization, peptide conjugation and cytotoxic activity
Here we present self-assembled polymeric micelles as potential delivery systems for therapeutic agents with highly tunable properties. The major goal of this study is to design breast and prostate cancer specific targeting peptide modified PEtOx-co-PEI-b-PCL block copolymer based micelles as a targetable carrier system in cancer treatment. For this, a series of micelles based on poly(2-ethyl-2-oxazoline)-co-polyethyleneimine-block-poly(ε-caprolactone) [P(EtOx-co-EI)-b-PCL] copolymers with two different proportions of PEI (30% and 60% hydrolysis degrees of PEtOx) were successfully prepared. The block copolymers were synthesized using a combination of living cationic ring-opening polymerization and a copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) click reaction. Then, peptide 18 and peptide 563 were conjugated to P(EtOx-co-EI)-b-PCL through a thiol–ene click-type reaction to obtain the desired tumor-targeting. The structural properties of the copolymers were confirmed by 1H NMR, FT-IR, UV-Vis spectrometry and GPC. Peptide and non-peptide-conjugated micelles with particle sizes between 82 ± 0.6 and 170 ± 10.7 nm were obtained by self-assembly with two different chain lengths of PEI blocks. The micelles containing the 60% PEI block showed increased zeta potential values. The cytotoxicity of the copolymers was evaluated under in vitro conditions. Overall, our results indicate that the micelles prepared with peptide-conjugated block copolymers can be used as potential nanocarriers for targeted therapeutic delivery systems.
- 16 November 2020
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 138 (17)
The synthesis of peptide‐conjugated poly(2‐ethyl‐2‐oxazoline)‐b‐poly(L‐lactide) (PEtOx‐b‐PLA) polymeric systems through the combination of controlled polymerization techniques and click reactions
To optimize the therapeutic effect of pharmaceutical agents, drug delivery systems tailored from FDA‐approved polymers like poly(L‐lactide) (PLA) is an effective strategy. Because of their hydrophobic character, these systems greatly suffer from reduced circulation time thus, amphiphilic block copolymers became favorable to overcome this limitation. Of them, poly(oxazoline)‐b‐poly(L‐lactide) are of choice as poly(oxazoline) (PEtOx) is compatible, biodegradable, while exhibiting minimum cytotoxicity. To tailor selective drug targeting drug delivery systems, whereby their selectivity for tumor tissues is maximized, these polymers should be decorated with so‐called tumor‐homing agents, such as antibodies, peptides and so forth. To this respect, we designed a new block copolymer, allyl‐poly(2‐ethyl‐2‐oxazoline)‐b‐poly(L‐lactide) allyl‐(PEtOx‐b‐PLA) and its subsequent conjugation to tumor‐homing peptides, peptide‐18, and peptide‐563 at the terminal position. In this manuscript, we report our synthetic route to obtain this building block and its conjugation to tumor‐homing agents.
- 16 November 2020
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 138 (17)
The synthesis of peptide‐conjugated poly(2‐ethyl‐2‐oxazoline)‐b‐poly(L‐lactide) (PEtOx‐b‐PLA) polymeric systems through the combination of controlled polymerization techniques and click reactions
To optimize the therapeutic effect of pharmaceutical agents, drug delivery systems tailored from FDA‐approved polymers like poly(L‐lactide) (PLA) is an effective strategy. Because of their hydrophobic character, these systems greatly suffer from reduced circulation time thus, amphiphilic block copolymers became favorable to overcome this limitation. Of them, poly(oxazoline)‐b‐poly(L‐lactide) are of choice as poly(oxazoline) (PEtOx) is compatible, biodegradable, while exhibiting minimum cytotoxicity. To tailor selective drug targeting drug delivery systems, whereby their selectivity for tumor tissues is maximized, these polymers should be decorated with so‐called tumor‐homing agents, such as antibodies, peptides and so forth. To this respect, we designed a new block copolymer, allyl‐poly(2‐ethyl‐2‐oxazoline)‐b‐poly(L‐lactide) allyl‐(PEtOx‐b‐PLA) and its subsequent conjugation to tumor‐homing peptides, peptide‐18, and peptide‐563 at the terminal position. In this manuscript, we report our synthetic route to obtain this building block and its conjugation to tumor‐homing agents.
- 7 July 2020
- Published by Taylor & Francis in International Journal of Polymeric Materials and Polymeric Biomaterials
- Vol. 70 (14) , 981-993
Synthesis, biocompatibility and gene encapsulation of poly(2-Ethyl 2-Oxazoline)-dioleoyl phosphatidylethanolamine (PEtOx-DOPE) and post-modifications with peptides and fluorescent dye coumarin
Liposome surface modifications serve great potential applications of liposomes, for instance, increasing stability, bioactive liposome conjugates, and targeted drug, gene, and image agent delivery. In this study, novel targeted lipopolymers, peptide 18/peptide 563-poly(2-ethyl-2-oxazoline)-dioleoylphosphatidyl-ethanolamine (P18/P563-PEtOx-DOPE), have been demonstrated to be successfully synthesized. The structures of P18/P563-PEtOx-DOPE were confirmed by FT-IR spectroscopy, GPC, and 1H-NMR. In this strategy, poly(2-ethyl 2-oxazoline)-modified liposomes were firstly constructed with molecular weights of 3,500 and 5,800 Da. Then, we chose PEtOx5800-DOPE because it has been obtained better particle size (88.74 ± 0.6816) according to the DLS results. Then, peptides- and dye-PEtOx lipid-based nanovesicle (LN) were prepared by peptide-18, peptide-563, and 7-mercapto-4-methyl coumarin. Genetic material (pDNA) was encapsulated into the liposomes and evaluated the encapsulation of plasmid DNA with migration by using agarose gel electrophoresis. In vitro cytotoxicity experiment results on prostate cancer and breast cancer cell lines, parallelly with the healthy prostate (PNT1A) and breast (MCF10A) epithelial cell lines, cells showed insignificant toxic effects. Thus, we can suggest a novel PEtOx phospholipid thanks to this article and its integration with ligands, which great potential for gene transfer system. Graphical Abstract
- 7 July 2020
- Published by Taylor & Francis in International Journal of Polymeric Materials and Polymeric Biomaterials
- Vol. 70 (14) , 981-993
Synthesis, biocompatibility and gene encapsulation of poly(2-Ethyl 2-Oxazoline)-dioleoyl phosphatidylethanolamine (PEtOx-DOPE) and post-modifications with peptides and fluorescent dye coumarin
Liposome surface modifications serve great potential applications of liposomes, for instance, increasing stability, bioactive liposome conjugates, and targeted drug, gene, and image agent delivery. In this study, novel targeted lipopolymers, peptide 18/peptide 563-poly(2-ethyl-2-oxazoline)-dioleoylphosphatidyl-ethanolamine (P18/P563-PEtOx-DOPE), have been demonstrated to be successfully synthesized. The structures of P18/P563-PEtOx-DOPE were confirmed by FT-IR spectroscopy, GPC, and 1H-NMR. In this strategy, poly(2-ethyl 2-oxazoline)-modified liposomes were firstly constructed with molecular weights of 3,500 and 5,800 Da. Then, we chose PEtOx5800-DOPE because it has been obtained better particle size (88.74 ± 0.6816) according to the DLS results. Then, peptides- and dye-PEtOx lipid-based nanovesicle (LN) were prepared by peptide-18, peptide-563, and 7-mercapto-4-methyl coumarin. Genetic material (pDNA) was encapsulated into the liposomes and evaluated the encapsulation of plasmid DNA with migration by using agarose gel electrophoresis. In vitro cytotoxicity experiment results on prostate cancer and breast cancer cell lines, parallelly with the healthy prostate (PNT1A) and breast (MCF10A) epithelial cell lines, cells showed insignificant toxic effects. Thus, we can suggest a novel PEtOx phospholipid thanks to this article and its integration with ligands, which great potential for gene transfer system. Graphical Abstract
- Open Access
- 25 June 2020
- Published by American Chemical Society (ACS) in ChemRxiv
The Synthesis of Peptide-Conjugated Poly(2-Ethyl-2-Oxazoline)-bpoly(L-Lactide) (PEtOx-B-PLA) Polymeric Systems Through the Combination of Controlled Polymerization Techniques and Click Reactions
To optimize the therapeutic effect of pharmaceutical agents, drug delivery systems tailored from FDA-approved polymers like poly(L-lactide) (PLA) is an effective strategy. Because of their hydrophobic character, these systems greatly suffer from reduced circulation time thus, amphiphilic block copolymers became favourable to overcome this limitation. Of them, poly(oxazoline)-b-poly(L-lactide) are of choice as poly(oxazoline) (PEtOx) is compatibile, biodegradable, while exhibiting minimum cytotoxicity. To tailor selective drug targeting drug delivery systems, whereby their selectivity for tumour tissues is maximised, these polymers should be decorated with so-called tumour-homing agents, such as antibodies, peptides and so forth. To this respect, we designed a new block copolymer, allyl-poly(2-ethyl-2-oxazoline)-b-poly(L-lactide) allyl-(PEtOx-b-PLA) and its subsequent conjugation to tumour-homing peptides, peptide-18 and peptide-563 at the terminal position. In this manuscript, we report our synthetic route to obtain this building block and its conjugation to tumour-homing agents.
- 25 June 2020
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessThe Synthesis of Peptide-Conjugated Poly(2-Ethyl-2-Oxazoline)-bpoly(L-Lactide) (PEtOx-B-PLA) Polymeric Systems Through the Combination of Controlled Polymerization Techniques and Click Reactions
To optimize the therapeutic effect of pharmaceutical agents, drug delivery systems tailored from FDA-approved polymers like poly(L-lactide) (PLA) is an effective strategy. Because of their hydrophobic character, these systems greatly suffer from reduced circulation time thus, amphiphilic block copolymers became favourable to overcome this limitation. Of them, poly(oxazoline)-b-poly(L-lactide) are of choice as poly(oxazoline) (PEtOx) is compatibile, biodegradable, while exhibiting minimum cytotoxicity. To tailor selective drug targeting drug delivery systems, whereby their selectivity for tumour tissues is maximised, these polymers should be decorated with so-called tumour-homing agents, such as antibodies, peptides and so forth. To this respect, we designed a new block copolymer, allyl-poly(2-ethyl-2-oxazoline)-b-poly(L-lactide) allyl-(PEtOx-b-PLA) and its subsequent conjugation to tumour-homing peptides, peptide-18 and peptide-563 at the terminal position. In this manuscript, we report our synthetic route to obtain this building block and its conjugation to tumour-homing agents.
- 19 August 2018
- Published by Springer Nature in Amino Acids
- Vol. 50 (11) , 1607-1616
Structure-based design, synthesis and anticancer effect of cyclic Smac–polyarginine peptides
The second mitochondria-derived activator of caspase (Smac/DIABLO) is a pro-apoptotic protein that released from mitochondria into the cytosol when cells undergo apoptosis. Smac promotes caspase activation by binding the inhibitors of apoptosis proteins (IAP), particularly XIAP and eliminating their inhibitory activity. Although the seven N-terminal amino acids AVPIAQK (SmacN7) of Smac protein is able to elicit an anticancer response by itself, it is neither cell-permeable nor stable in the cellular environment. Thus, the use of SmacN7 derivatives and mimetics is an alluring field for cancer therapy. In this study, heptamer Smac peptide was fused to a well-known octaarginine cell-penetrating peptide for promoting its intracellular access. Both therapeutic Smac part and cell-penetrating octaarginine parts of the peptide sequence constrained in a cyclic structure so as to enhance the apoptosis-inducing potential of the SmacN7 peptide. Biological assays interestingly showed that cyclic peptides P4, P5 and P7 gave rise to a significant level of cytotoxicity and apoptosis mediated cell death in multiple myeloma tumor cells (MM) comparing to linear peptide.
- 19 August 2018
- Published by Springer Nature in Amino Acids
- Vol. 50 (11) , 1607-1616
Structure-based design, synthesis and anticancer effect of cyclic Smac–polyarginine peptides
The second mitochondria-derived activator of caspase (Smac/DIABLO) is a pro-apoptotic protein that released from mitochondria into the cytosol when cells undergo apoptosis. Smac promotes caspase activation by binding the inhibitors of apoptosis proteins (IAP), particularly XIAP and eliminating their inhibitory activity. Although the seven N-terminal amino acids AVPIAQK (SmacN7) of Smac protein is able to elicit an anticancer response by itself, it is neither cell-permeable nor stable in the cellular environment. Thus, the use of SmacN7 derivatives and mimetics is an alluring field for cancer therapy. In this study, heptamer Smac peptide was fused to a well-known octaarginine cell-penetrating peptide for promoting its intracellular access. Both therapeutic Smac part and cell-penetrating octaarginine parts of the peptide sequence constrained in a cyclic structure so as to enhance the apoptosis-inducing potential of the SmacN7 peptide. Biological assays interestingly showed that cyclic peptides P4, P5 and P7 gave rise to a significant level of cytotoxicity and apoptosis mediated cell death in multiple myeloma tumor cells (MM) comparing to linear peptide.
- Open Access
- 3 August 2018
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF CHEMISTRY
- Vol. 42 (4) , 1136-1145
The design and synthesis of a photo-controlled, peptide-based potential drug carrier
- 3 August 2018
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF CHEMISTRY
- Vol. 42 (4) , 1136-1145
Open AccessThe design and synthesis of a photo-controlled, peptide-based potential drug carrier
- 1 September 2012
- Published by Elsevier in New Biotechnology
- Vol. 29, S91-S92
Biocatalytic resolution of multifunctional phosphonates
- 1 September 2012
- Published by Elsevier in New Biotechnology
- Vol. 29, S91-S92
Biocatalytic resolution of multifunctional phosphonates